...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Development of novel amide–derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: Identification of the cyclopropylamide moiety as a key modification
【24h】

Development of novel amide–derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: Identification of the cyclopropylamide moiety as a key modification

机译:新型酰胺衍生化的2,4-双吡啶基噻吩是高效和选择性的甲孔抑制剂。 第二部分:将环丙基酰胺部分的鉴定为关键改性

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A) is a potential target in Alzheimer's disease (AD) because of the established correlation between its over-expression and generation of neurofibrillary tangles (NFT) as well as the accumulation of amyloid plaques. However, the use of Dyrk1A inhibitors requires a high degree of selectivity over closely related kinases. In addition, the physicochemical properties of the Dyrk1A inhibitors need to be controlled to enable CNS permeability. In the present study, we optimized our previously published 2,4-bispyridyl thiophene class of Dyrk1A inhibitors by the synthesis of a small library of amide derivatives, carrying alkyl, cycloalkyl, as well as acidic and basic residues. Among this library, the cyclopropylamido modification (compound4b) was identified as being highly beneficial for several crucial properties.4bdisplayed high potency and selectivity against Dyrk1A over closely related kinases in cell-free assays (IC50: Dyrk1A?=?3.2?nM; Dyrk1B?=?72.9?nM and Clk1?=?270?nM) and inhibited the Dyrk1A activity in HeLa cells with high efficacy (IC50: 43?nM), while no significant cytotoxicity was observed. In addition, the cyclopropylamido group conferred high metabolic stability and maintained the calculated physicochemical properties in a range compatible with a potential CNS activity. Thus, based on its favourable properties,4bcan be considered as a candidate for furtherin?vivotesting in animal models of AD.
机译:双特异性酪氨酸磷酸化调节的激酶1a(Dyrk1a)是阿尔茨海默病(Ad)的潜在靶标,因为其过度表达与神经原纤维缠结(NFT)的产生与淀粉样斑块的积累之间的相关性以及淀粉样蛋白斑块之间的累积。然而,使用Dyrk1a抑制剂需要高度选择性与密切相关的激酶。此外,需要控制达克1A抑制剂的物理化学性质以使CNS渗透性能够。在本研究中,我们通过合成了酰胺衍生物的小文库,携带烷基,环烷基以及酸性和碱性残留物,优化了先前公布的2,4-双吡啶族蛋白类别的Dyrk1A抑制剂。在该文库中,依赖环丙基酰胺修饰(化合物4b)对于几种关键特性,对若干关键性质具有高度有益.4bd叠现的高效力和针对细胞 - 无关的激酶在无细胞测定中密切相关的激酶的高效力和选择性(IC50:dyrk1a?= 3.2?nm; dyrk1b? =?72.9?nm和clk1?=Δ270≤nm)并抑制高疗效(IC50:43≤nm)的HeLa细胞中的司司氏菌活性,同时观察到没有显着的细胞毒性。此外,环丙基氨基基团赋予高代谢稳定性,并在与潜在的CNS活性相容的范围内保持计算的物理化学性质。因此,根据其有利的属性,4BCAN被视为进一步的候选人?在广告的动物模型中维持活力。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号